Hims & Hers Health (NYSE:HIMS) shares were on a massive run, but that momentum hit a wall recently. Since its peak on ...

Former US Army Sgt. Mark Millich’s sex drive plummeted — and his genitals shrank and changed shape after taking popular hair-loss drug finasteride.

Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...

Hims and other telehealth companies make finasteride easy to get and don’t have to disclose side effects in ads.

Roller-coaster healthcare stock Hims & Hers Health ( HIMS -1.34%), whose stock got devastated last week by worries that it ...

With Hims & Her's main source of growth set to be extinguished, Citi analysts said its full-year guidance appears "aspirational." ...

Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...

News About the Weight-Loss Drugs Is Pressuring HIMS Stock Eli Lilly disclosed today that it had started selling 7.5 milligram and 10 milligram vials of Zepbound, its popular weight-loss drug, for ...

Hims & Hers (HIMS) stock is sinking 20% today after Eli Lilly (LLY) unveiled significantly cheaper versions of its popular weight-loss drugs today. Additionally, the FDA last week hindered the ...

Hims & Hers (HIMS) stock plunged 27% on Tuesday after the telehealth highflier indicated it may soon stop offering some compounded versions of weight-loss drugs. The company's fourth quarter ...

Direct-to-consumer telehealth company Hims & Hers is forging ahead in the aftermath of the semaglutide shortage ending last week. Hims & Hers faces new headwinds in its weight management segment ...